Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Penn Vet's Ebola Resource Kit


As Ebola continues to dominate the news, we want to provide you with the latest information on Penn Vet faculty involved in the study of this deadly virus. Below you'll find a list of our experts available for commentary, information about our research and antiviral therapeutics, current news articles, and multimedia resources.

ebola-screencap2
Intervir, Penn Vet

What is Intervir?

Intervir is a privately held company founded in 2013 as part of the Penn Center for Innovation's UPstart Program. The company is dedicated to discovering novel drugs to treat viral disease. Its technology and science is based on the work of Penn Vet's Dr. Bruce Freedman and Dr. Ronald Harty.   

Media Contacts

John Donges
Communications Coordinator
jdonges@vet.upenn.edu
215-898-4234

Hannah Kleckner
Communications Specialist for New Bolton Center
hkleck@vet.upenn.edu
610-925-6241



Meet Our Experts

Penn Vet Faculty Studying Ebola
   Name Title  Area of Expertise
Penn Vet, Daniel Beiting
Daniel Beiting, PhD
  • Research Assistant Professor of Pathobiology
  • Technical Director, Center for Host-Microbial Interactions
  • Host pathogen interactions
Dr. Bruce Freedman, Penn Vet
Bruce Freedman, VMD/PhD
  • Associate Professor of Pathobiology
  • Director, Penn Vet Imaging Core
  • Viral signaling mechanisms
  • Antiviral therapeutics
  • Advanced optical imaging
Ron Harty, PhD, Penn Vet
Ronald Harty, PhD
  • Associate Professor of Microbiology
  • Treatment of zoonoses
  • Antiviral therapeutics
Dr. Gary Smith, Penn Vet
Gary Smith, DPhil
  • Professor of Population Biology and Epidemiology
  • Epidemiology
  • Public health
  • Social impact of Ebola

Penn Vet In the News: Ebola Coverage

Multimedia

Ebola Buds on Cell Surface

This 3D rendering shows a human cell (red) and non-infectious Ebola “virus-like particles” (green projections) budding from the surface of the cell. Ebola virus VP40 protein, when introduced into human cells, initiates this budding process by a mechanism that accurately mimics budding or release of live infectious Ebola virus. This approach enables Penn Vet researchers to study the budding and transmission process safely in the lab and helps them dissect the mechanisms of Ebola virus pathogenesis. The state-of-the-art instrumentation in the Penn Vet Imaging Core allows them to visualize this budding process in live cells in real time. This approach has provided important insights that support Penn Vet's ongoing efforts to develop small molecule inhibitors of live Ebola virus budding. Drs. Freedman and Harty have tested a number of novel budding inhibitors on live Ebola virus in collaboration with the United States Army Medical Research Institute of Infectious Disease (USAMRIID). Their objective is to commercialize this work through a company established through the University of Pennsylvania called Intervir Therapeutics.

Image from the lab of Dr. Bruce Freedman, as part of a long-standing collaboration with Dr. Ronald Harty. Image produced by Jon Madara and Dr. Gordon Ruthel.

Ebola: Viral Budding

This video shows Ebola VP40 (tagged with green fluorescent protein) budding in real-time from the surface of live human cells in the form of long filamentous virus-like particles. These particles mimic budding of live infectious Ebola virus, which happens at the surface of the cell.

Image from the lab of Dr. Bruce Freedman, as part of a long-standing collaboration with Dr. Ronald Harty. Image produced by Jon Madara and Dr. Gordon Ruthel.